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SiRT3 in Cardiac Physiology and 
Disease
Christoph Koentges, Christoph Bode and Heiko Bugger*
Division of Cardiology and Angiology I, Heart Center Freiburg University, Freiburg, Germany
Functional defects in mitochondrial biology causally contribute to various human diseases, 
including cardiovascular disease. Impairment in oxidative phosphorylation, mitochondrial 
oxidative stress, and increased opening of the mitochondrial permeability transition pore 
add to the underlying mechanisms of heart failure or myocardial ischemia–reperfusion 
(IR) injury. Recent evidence demonstrated that the mitochondrial NAD+-dependent 
deacetylase sirtuin 3 (SIRT3) may regulate these mitochondrial functions by reversible 
protein lysine deacetylation. Loss of function studies demonstrated a role of impaired 
SIRT3 activity in the pathogenesis of myocardial IR injury as well as in the development 
of cardiac hypertrophy and the transition into heart failure. Gain of function studies and 
treatment approaches increasing mitochondrial NAD+ availability that ameliorate these 
cardiac pathologies have led to the proposal that activation of SIRT3 may represent a 
promising therapeutic strategy to improve mitochondrial derangements in various car-
diac pathologies. In the current review, we will present and discuss the available literature 
on the role of SIRT3 in cardiac physiology and disease.
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iNTRODUCTiON
The sirtuin family of protein deacetylases consists of seven mammalian members (SIRT1-7), which 
are orthologs of the silent information regulator two (Sir2) that was first identified in yeast almost 
two decades ago (1, 2). Sirtuins are classified as class III histone deacetylases, requiring NAD+ as a 
cosubstrate, which acts as an acceptor molecule for the acetyl group removed from the target protein 
(3). The need of NAD+ as a cosubstrate links activity of sirtuins tightly to the cellular energy status 
making them potential redox sensors (4–6). SIRT3, SIRT4, and SIRT5 are primarily localized inside 
the mitochondria, and SIRT3 possesses the most robust deacetylase activity of all mitochondrial 
sirtuins (7, 8). Although named histone deacetylases, numerous non-histone protein targets have 
been identified using large-scale proteomic analyses, also including proteins localized outside of 
mitochondria (9, 10). Deacetylation targets of SIRT3 include metabolic enzymes involved in fatty 
acid oxidation (FAO) and glucose oxidation (GLOX), protein subunits of the electron transport 
chain (ETC), as well as enzymes involved in oxidative stress defense and mitochondrial integrity 
(7, 10–21).
SIRT3 is highly expressed in tissues with high metabolic turnover and mitochondrial content, 
including the heart and its role in cardiac physiology and pathology have been increasingly inves-
tigated in recent years (8, 17, 22–29). Under normal physiologic conditions, about 95% of ATP 
used to maintain cardiac pump function is regenerated within mitochondria by the oxidation of 
fatty acids and glucose, with some contribution from other substrates as well (30). Mitochondrial 
derangements such as defects in substrate oxidation and oxidative phosphorylation, mitochondrial 
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oxidative stress, and increased sensitivity for opening of the 
mitochondrial permeability transition pore (mPTP) are major 
mechanisms underlying clinically important cardiac patholo-
gies, such as heart failure and ischemia–reperfusion (IR) injury 
(31–36). A number of studies provided evidence that SIRT3 
regulates these mechanisms in the heart. In this review, we will 
present and discuss the current knowledge on the role of SIRT3 in 
cardiac physiology and disease and potential therapeutic strate-
gies aiming at modulating SIRT3 activity.
SiRT3 iN CARDiAC PHYSiOLOGY
SiRT3 and Cardiac Function
The impact of SIRT3 in the regulation of cardiac function has been 
evaluated in a number of studies using mice with global deletion 
of SIRT3 (SIRT3−/−) (13, 17, 22–26, 29). Using echocardiography, 
fractional shortening (FS) and ejection fraction (EF) were not 
different between SIRT3−/− and wild-type (WT) mice at 8 weeks 
of age (17, 23, 25, 28, 29, 37). However, in older animals (24 weeks 
of age), SIRT3−/− mice displayed a decrease in EF and FS, accom-
panied by increased systolic and diastolic diameters and volumes 
of the left ventricle (LV) indicative of LV dilation (23, 28). Thus, 
SIRT3−/− mice seem to develop an accelerated age-related decline 
in cardiac contractile function (23, 28). Interestingly, when 
perfused in the isolated working heart model, even 8-week-old 
SIRT3−/− mice display contractile defects, such as a decrease in 
cardiac power, cardiac output, and developed pressure (22, 23). 
Possibly, contractile dysfunction could not be observed in young 
mice in vivo but only ex vivo since neurohormonal compensatory 
mechanisms may only be present in the live animal (e.g., renin–
angiotensin–aldosterone–system, autonomic nervous system, 
changes in vasomotor and/or heart rate), but absent in isolated 
perfused hearts. With increasing age, the progress in cardiac 
remodeling due to SIRT3 deficiency (e.g., increased fibrosis, LV 
dilation) may dominate these compensatory mechanisms leading 
to obvious cardiac dysfunction detectable by echocardiography. 
Furthermore, aging-associated abnormalities in mitochondrial 
function, such as increased oxidative stress, mutations of mito-
chondrial DNA, and decreased mitochondrial respiration may 
predispose for a stronger impact of SIRT3 deficiency on overall 
mitochondrial function and integrity in older versus younger 
mice (38). Interestingly, one study did not observe impairment 
in contractile function in 24- to 26-week-old mice in isolated 
working hearts (24). In this study though, hearts were perfused 
in the presence of insulin and higher concentrations of fatty acids 
compared to Koentges and colleagues (23). The impact of insulin 
and substrate availability on cardiac function and energetics in 
SIRT3−/− mice remains to be determined in more detail.
Further evidence supporting the proposal of SIRT3 being 
required to maintain cardiac function comes from studies that 
increased cardiac energy demand by increasing cardiac workload. 
Following transverse aortic constriction (TAC), SIRT3−/− mice 
display an accelerated development of contractile dysfunction 
with a more pronounced decrease in EF and a more pronounced 
increase in endsystolic volume (23). Under these conditions, 
SIRT3−/− mice develop a greater degree of cardiac fibrosis and 
a more pronounced increase in cardiomyocyte hypertrophy 
(13, 17, 23, 25). Vice versa, Sundaresan et al. could prevent cardiac 
contractile dysfunction and attenuate the extent of fibrosis after 
angiotensin II (AngII) infusion by cardiomyocyte-specific over-
expression of SIRT3 (17). Interestingly, TAC-induced contractile 
dysfunction with concomitant reduction of SIRT3 expression 
in WT mice was rescued by reinduction of SIRT3 expression by 
administration of honokiol, a compound derived from magnolian 
trees (39). Taken together, these studies suggest that SIRT3 seems 
to be required to maintain cardiac contractile function.
Targets and Pathways Regulated by SiRT3
Cardiac function is tightly linked to the continuous delivery of 
energy-rich phosphates, 95% of which are generated by mito-
chondrial oxidative phosphorylation. Quite a number of studies 
reported that SIRT3 regulates energy metabolism in various tis-
sues, including the heart. Hirschey et al. reported decreased rates of 
palmitate oxidation in cardiac tissue extracts from SIRT3−/− mice, 
and Ahn et al. reported lower cardiac ATP levels in these mice 
(16, 40). These findings were confirmed in isolated working heart 
experiments showing decreased rates of palmitate and GLOX and 
lower rates of myocardial O2 consumption in SIRT3−/− mice (23). 
In addition, isolated cardiac mitochondria showed lower rates of 
ATP production, resulting in lower ATP/AMP ratios, and thus 
decreased cellular energy charge (23). Impairment in mitochon-
drial function may be the consequence of hyperacetylation of 
several SIRT3 target enzymes in the absence of SIRT3. SIRT3 
target enzymes range through almost all substrate oxidation and 
ATP-generating processes from pyruvate import (mitochondrial 
pyruvate carrier), TCA cycle activity and its anaplerosis (acetyl-
CoA synthetase, aconitase, glutamate dehydrogenase, isocitrate 
dehydrogenase), β-oxidation of fatty acids (long-chain acyl-CoA 
dehydrogenase), to oxidative phosphorylation (Ndufa9, succinate 
dehydrogenase and ATP synthetase subunit a) and ATP translo-
cation (adenine nucleotide translocase) (7, 11, 12, 14, 16, 19, 20, 
23, 40, 41). Most of the described targets of SIRT3 are thought to 
be activated by SIRT3-mediated protein deacetylation.
Since SIRT3 activity is directly linked to the NAD+/NADH 
ratio, SIRT3 may serve as a metabolic sensor. In situations of high 
energy demand, the NAD+/NADH ratio rises and subsequently 
increases SIRT3 activity, which may translate into deacetylation 
of metabolic enzymes and thus acceleration of metabolic path-
way flux and energy production. A dysbalance between energy 
demand and supply may occur during physical exercise or changes 
in blood pressure or during the 24-h fasting and feeding cycle, 
when NAD+ levels oscillate in a circadian fashion (42). Given the 
fact that SIRT3 drives mitochondrial substrate oxidation and thus 
ETC flux, it is not surprising that SIRT3 participates in the detoxi-
fication of reactive oxygen species (ROS). Manganese superoxide 
dismutase (MnSOD), a major intramitochondrial antioxidant 
enzyme, has been reported to be a deacetylation target of SIRT3, 
and MnSOD expression is also controlled by SIRT3-mediated 
nuclear translocation of the transcription factor forkhead-box-
protein 3a (Foxo3a) (17, 43, 44). SIRT3 may, thereby, protect the 
heart from oxidative damage induced by increased production 
of ROS, which may result as byproducts of accelerated ETC flux.
Of note, the assumption that a lower degree of lysine acety-
lation is connected to a higher activity of the affected enzyme 
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should be drawn carefully. Although most of the described 
deacetylation targets of SIRT3 are activated by deacetylation, 
Fernandes et al. recently reported that increased acetylation of 
aconitase 2 (ACO2) increases ACO2 enzymatic activity (12). 
The authors argue that lower expression of SIRT3 induced by 
high-fat diet feeding may increase ACO2 activity, which may 
increase cytosolic citrate levels and subsequently inhibit acetyl-
CoA-carboxylase, resulting in lower malonyl-CoA levels and 
subsequent derepression of carnitine-palmitoyl transferase 
(12). Lower SIRT3 levels would, thereby, adapt mitochondrial 
β-oxidation to higher levels of circulating fatty acids. In another 
study, Alrob et al. reported decreased SIRT3 protein levels after 
feeding a high-fat diet, which was associated with higher acetyla-
tion levels of long-chain acyl-CoA dehydrogenase (LCAD) and 
3-hydroxyacyl-CoA dehydrogenase leading to higher enzyme 
activity and FAO rates (24). Of interest, increased acetylation 
of LCAD has been reported to both increase and decrease its 
activity. One possible explanation for these conflicting results 
may be differences in the acetylation pattern of LCAD, which 
may differentially affect enzymatic activity. For example, p53 
possesses 13 potential acetylation sites in different domains (45). 
Mathematically, 6,227,020,800 different combinations of lysine 
acetylations would be possible, which may change p53 protein 
function. To date, only few data are available on specific acetyla-
tion patterns induced by SIRT3 or SIRT3 deficiency and the effect 
on target enzyme activity.
SiRT3 expression in the Heart
SIRT3 is highly expressed in organs with high metabolic turno-
ver, e.g., heart, liver, brain, and kidney (40). In the heart, SIRT3 
expression responds to changes in energy demand (16, 23, 25, 27, 
29, 39, 46). In mice, myocardial SIRT3 expression was increased 
following TAC or infusion of isoproterenol or AngII, prob-
ably to match oxidative capacity to increased demand for ATP 
regeneration in hypertrophied hearts (17, 23). In contrast though, 
when hypertrophy progresses to heart failure, or in doxorubicin-
induced heart failure, expression of SIRT3 was decreased (25, 27, 
47). Similarly, SIRT3 expression was decreased in human failing 
hearts (48, 49). Thus, the downregulation of SIRT3 may rather be 
maladaptive in the failing heart and may exaggerate mitochon-
drial dysfunction and oxidative stress.
A downregulation of SIRT3 was also observed in hearts of mice 
fed a high-fat diet, in obese, and type 2 diabetic db/db mice, and in 
rodents with streptozotocin-induced type 1 diabetes, suggesting 
that downregulation of SIRT3 in the heart may also be a hallmark 
of the metabolic syndrome and diabetes mellitus, although a 
downregulation of SIRT3 was not observed in every single study 
(24, 28, 50–52). Similar to failing hearts, SIRT3 downregulation 
may also contribute to myocardial mitochondrial dysfunction 
and oxidative stress in diabetes, but may also contribute to 
reduced capillary density in diabetic hearts (28, 50, 53).
Upstream signaling that regulates SIRT3 expression is 
poorly understood, but may involve the master regulator of 
mitochondrial biogenesis and gene expression, peroxisome 
proliferator-activated receptor gamma coactivator 1 α (PGC-1α). 
Kong et al. demonstrated that PGC-1α regulates SIRT3 expres-
sion via binding of ERRα to an ERR response element on the 
SIRT3 promoter in C2C12 myotubes (54). In skeletal muscle, 
dihydromyricetin improved insulin sensitivity by induction of 
autophagy via activation of the AMPK-PGC-1α-Sirt3 signaling 
pathway (55). Thus, SIRT3 expression may be regulated by PGC-
1α, and reduced expression of SIRT3 in heart failure may thus be 
related to downregulation of PGC-1α in failing hearts (48, 49, 56). 
This hypothesis, however, remains to be tested experimentally.
SiRT3 iN CARDiAC DiSeASe
SiRT3 in Hypertrophy and Heart Failure
Increasing evidence suggests a causative role of impaired SIRT3 
activity in a number of cardiac pathologies, including cardiac 
hypertrophy and heart failure. SIRT3−/− mice spontaneously 
develop cardiac hypertrophy with increasing age (13, 17, 23, 29). 
The hypertrophic response to pressure overload (induced by 
TAC), treatment with AngII, or infusion of isoproterenol is more 
pronounced in SIRT3−/− mice compared with non-transgenic 
controls (13, 17, 23, 29). The exacerbated hypertrophy is accom-
panied by a more pronounced increase in interstitial fibrosis as 
well. Conversely, overexpression or pharmacological activation of 
SIRT3 was able to ameliorate or even block cardiac hypertrophy 
and interstitial fibrosis in response to pressure overload or hyper-
trophy agonist treatment (17, 29, 47).
Several mechanisms may contribute to the beneficial and 
deleterious effects of SIRT3 activation and deletion, respec-
tively. SIRT3 has numerous targets in mitochondrial energy 
metabolic pathways, which are hyperacetylated in mice lacking 
SIRT3. A coordinated slowing of FAO, GLOX, the TCA cycle, 
and oxidative phosphorylation with subsequent myocardial 
energy depletion due to decreased SIRT3 activity may, thus, be 
a plausible mechanism contributing to contractile dysfunction 
and impaired adaptation to increased energy demands (23, 40). 
Another important mechanism may be an imbalance between 
ROS production and expression and activity of antioxidative 
enzymes, resulting in oxidative stress. SIRT3−/− mice show signs 
of increased oxidative stress, e.g., increased levels of 4-HNE and 
TBARS (15, 23). Vice versa, overexpression of SIRT3 prevents 
ROS accumulation during hypertrophy, probably by preventing 
a drop in catalase and MnSOD expression after AngII infusion, 
likely due to an increase in FOXO3a signaling (17). In addition, 
SIRT3 is capable of deacetylating MnSOD, thereby increasing 
its activity and attenuating oxidative stress (17). Protection 
from oxidative stress may also attenuate activation of the ROS-
sensitive MAPK/ERK and PI3K/AKT signaling pathways, which 
are known to play a major role in the development of cardiac 
hypertrophy (57). Cytosolic ROS may be of minor importance 
though, since ROS scavenging by treatment with the antioxidant 
4-hydroxy-2,2,6,6-tetramethylpiperidin-1-oxyl (TEMPOL) did 
not improve contractile deficits in hearts of SIRT3−/− mice (23). 
Increased fibrosis in aged SIRT3−/− mice and following TAC may 
be related to a disinhibition of transforming growth factor β1 
(TGF-β1) signaling and hyperacetylation of glycogen synthase 
kinase 3β (GSK3β) by SIRT3 deficiency, resulting in increased 
expression of profibrotic genes (58).
The above mentioned mechanisms may well contribute to 
mitochondrial dysfunction typically observed in failing hearts. 
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Indeed, SIRT3 expression is reduced and global mitochondrial 
protein lysine acetylation is increased in rodent models of heart 
failure, suggestive of impaired SIRT3 activity (48). Reduced SIRT3 
expression may be the consequence of PGC-1α downregulation, 
suggesting that impaired PGC-1α-SIRT3 signaling may impair 
mitochondrial function by several mechanisms, including inhi-
bition of substrate oxidation due to enzyme hyperacetylation, 
increased oxidative stress, and impaired OXPHOS expression 
due to impaired PGC-1α signaling per  se. Another mechanism 
which may impair SIRT3 activity in failing hearts may be NAD+ 
depletion or a decrease in the NAD+/NADH ratio. Poly(ADP-
ribose)-polymerase 1 (PARP-1) is a DNA repair enzyme which is 
overactivated in failing hearts, and PARP-1 also uses NAD+ as a 
cosubstrate (59). Overactivation of PARP-1 leads to cellular NAD+ 
depletion, potentially resulting in impaired SIRT3 activity (59, 
60). A decrease in the NAD+/NADH ratio may also be caused by 
preexisting mitochondrial dysfunction per se. Karamanlidis et al. 
demonstrated a decrease in the NAD+/NADH ratio in a mouse 
model with complex I (Ndufs4 subunit) deficiency, resulting in 
heart failure (5). Since protein levels of SIRT3/4/5 were unchanged, 
they proposed that inhibition of SIRT3 activity by a low NAD+/
NADH ratio may have caused hyperacetylation of mitochondrial 
proteins, which would further impair the preexisting mitochon-
drial dysfunction due to complex I deficiency. Indeed, restoration 
of the NAD+/NADH ratio by treatment with β-nicotinamide 
mononucleotide (NMN) decreased mitochondrial protein acety-
lation in mice with complex I deficiency (5). Thus, both, reduced 
expression of SIRT3 and a decrease in NAD+ availability may 
contribute to impaired SIRT3 activity in heart failure.
SiRT3 in iR injury
Mitochondria play a pivotal role in the pathogenesis of myo-
cardial IR injury. Impaired mitochondrial respiration, mito-
chondrial oxidative stress, and increased opening of the mPTP 
determine myocardial infarct size and recovery of contractile 
function following an ischemic episode (61, 62). Porter et  al. 
reported pronounced impairment in recovery of contractile 
function and an increase in myocardial infarct size follow-
ing ischemia in 28-week-old SIRT3+/− mice compared with 
WT controls (26). Regarding the mechanisms, SIRT3+/− mice 
showed a decrease in complex I activity, suggesting impairment 
in mitochondrial function, and a decrease in MnSOD activity, 
suggesting impaired oxidative stress defense (26). In addition, 
Hafner et al. reported increased sensitivity for mPTP opening 
in SIRT3−/− mice, likely due to deacetylation of lysine 166 of 
cyclophilin D, a critical component of the mPTP (13). Since 
mitochondrial NAD+ levels drop during myocardial IR in WT 
mice, SIRT3 activity may be impaired during IR and, thus, 
contribute to IR injury in the heart (63).
Of interest and in contrast to SIRT3 heterozygous mice, 
SIRT3−/− mice showed no additional impairment in recovery 
of contractile function following global no-flow ischemia in the 
isolated working heart model (22). In addition, rates of mito-
chondrial O2 consumption, 4-HNE levels, and Ca2+-induced 
mitochondrial swelling were not different to WT controls under-
going IR (22). However, SIRT3−/− mice were younger (8 weeks 
of age) compared with 6-month-old mice in the study by Porter 
and colleagues (26). Thus, these results suggest an age-dependent 
increase in susceptibility for IR injury in SIRT3−/− mice. In fact, 
the extent of IR injury generally increases with age, accompanied 
by abnormalities of mitochondrial biology, such as increased ROS 
production, decreased mitochondrial cristae density, and impair-
ment in oxidative phosphorylation and ETC complex activities 
(64–71). Thus, it is tempting to speculate that lack of SIRT3 per se 
may not necessarily aggravate IR injury, but with increasing age, 
the presence of additional defects in mitochondrial function may 
ultimately increase the overall vulnerability of SIRT3−/− mice for 
cardiac damage following myocardial IR. Of note, it has been 
reported that the expression of SIRT3 decreases with increasing 
age in various organs in mice (kidney, brain, aortic valve tissue), 
and that NAD+ levels also drop with increasing age in C. elegans 
and liver and skeletal muscle tissue in mice (37, 72–76). Thus, 
a combination of decreased SIRT3 expression and activity may 
contribute to a greater extent of IR injury with increasing age.
SiRT3 AS A POTeNTiAL THeRAPeUTiC 
TARGeT
Based on the evidence presented in the previous paragraphs, 
impaired SIRT3 activity may play an important role in the 
pathogenesis of cardiac hypertrophy, heart failure, and IR injury. 
Thus, different pharmacological approaches have been pursued 
to either increase SIRT3 expression or to increase SIRT3 activity 
by raising NAD+ levels (Figure 1). Honokiol is a polyphenol that 
belongs to a class of neolignan biphenols and that has a high 
bioavailability. It is derived from bark of magnolian trees and has 
been widely used in traditional medicine in China, Korea, and 
Japan. Honokiol may exert a large number of effects, including 
anti-inflammatory effects, anti-apoptotic effects, antioxidant 
effects, anti-tumorigenic effects, may activate PPARγ signaling, 
and interferes with MAPK and PI3K/Akt signaling, among 
several other effects (77, 78). Pillai et  al. recently showed that 
the administration of honokiol is capable of reversing cardiac 
hypertrophy and of rescuing contractile dysfunction following 
TAC in mice (39). The authors showed that honokiol was present 
within mitochondria and enhanced SIRT3 expression nearly 
two-fold, accompanied by reduced deacetylation of mitochon-
drial SIRT3 target proteins (39). Another natural biphenol that 
is contained in the skin of grapes, blueberries, and raspberries 
and that may modulate SIRT3 activity, is resveratrol (RSV). 
RSV exerts multiple effects on the cardiomyocyte, including 
AMPK activation, induction of autophagy, inhibition of ROS 
production, vasorelaxation, inhibition of atherosclerosis, anti-
inflammatory effects, and boosting mitochondrial biogenesis, 
using many different signaling pathways outlined in more detail 
elsewhere (79, 80). Regarding sirtuins, RSV was originally 
reported to activate SIRT1 and is thought to decrease the risk 
of heart disease (79). Chen et al. recently reported though that 
RSV prevented cardiac hypertrophy in response to hypertrophic 
stimuli in WT mice, and this protective effect was not observed 
in SIRT3 knockout mice (81). In addition, the activation of 
SIRT3 by RSV attenuated collagen deposition and improved 
cardiac contractile function (81).
FiGURe 1 | Beneficial effects of increased SiRT3 activity. Pharmacological activation and/or induction of SIRT3 expression may protect against cardiac 
hypertrophy, heart failure, and ischemia–reperfusion injury by improving mitochondrial substrate oxidation, decreasing prohypertrophic signaling, attenuating 
oxidative stress, and maintaining mitochondrial integrity. OXPHOS, oxidative phosphorylation; FAO, fatty acid oxidation; GLOX, glucose oxidation; MnSOD, 
manganese superoxide dismutase; ROS, reactive oxygen species; mPTP, mitochondrial permeability transition pore.
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Yet another approach to increase SIRT3 activity is by elevating 
NAD+ levels by feeding the NAD+ salvage pathway using the 
NAD+ precursor molecule NMN. By administration of NMN, 
Pillai et al. could attenuate phenylephrine-induced cardiomyocyte 
hypertrophy in neonatal rat cardiomyocytes and AngII-induced 
cardiac hypertrophy in mice (29). Importantly, they also dem-
onstrated that NMN treatment attenuated isoproterenol-induced 
cardiac hypertrophy, a beneficial effect that was blunted in mice 
with additional SIRT3 deficiency (29). Even more impressive, 
Lee et al. recently demonstrated that normalization of the NAD+ 
redox balance by NMN treatment or overexpression of the rate-
limiting enzyme for NAD+ synthesis, nicotinamide phospho-
ribosyltransferase (Nampt), improved cardiac hypertrophy and 
dysfunction induced by isoproterenol treatment or TAC, strongly 
suggesting that NAD+ repletion may represent a promising thera-
peutic approach to treat cardiac hypertrophy and heart failure 
(82). Similar positive effects of NAD+ repletion were observed 
in the setting of IR, where NAD+ is lost during reperfusion 
(63). Reraising NAD+ levels by overexpression of Nampt or by 
administration of NMN resulted in reduced myocardial infarct 
size following IR (63, 83). Although none of the above mentioned 
substances (honokiol, RSV, NMN) is a specific activator of SIRT3, 
the results are encouraging that specific activation of SIRT3 as a 
therapeutic strategy may have beneficial effects in heart disease.
OTHeR MiTOCHONDRiAL SiRTUiNS
SIRT4 and SIRT5 are further mitochondrial sirtuins that require 
NAD+ as a cosubstrate and which seem to oppose or complement 
the function of SIRT3 in the heart. Thus far, only few is known 
about SIRT4 and SIRT5 in general, compared with SIRT3. While 
the in  vitro deacetylation activity of SIRT4 seems to be much 
lower compared with SIRT3, other posttranslational modifica-
tions may be of higher relevance, such as delipoylation and ADP 
ribosylation, although the latter one may simply represent a side 
reaction of the main deacylation activity without significant 
physiological relevance (84–87). SIRT4 has been shown to regu-
late energy metabolism by inhibiting glutamate dehydrogenase 
by ADP ribosylation, to inhibit the pyruvate dehydrogenase 
complex by hydrolyzing the lipoamide cofactors from the E2 
component dihydrolipoyllysine acetyltransferase, and to regulate 
lipid metabolism by deacetylating malonyl-CoA decarboxylase, 
resulting in malonyl-CoA accumulation and inhibition of FAO 
(85–87). SIRT4 is highly expressed in the heart, but does not seem 
to affect the physiologic pump function of the heart when geneti-
cally overexpressed or deleted (88). In contrast, increased cardiac 
hypertrophy and aggravated cardiac dysfunction have been 
observed in response to AngII treatment in mice with cardiomy-
ocyte-restricted overexpression of SIRT4 (88). Mechanistically, 
mitochondria-targeted antioxidant treatment prevented the 
aggravation of cardiac hypertrophy in SIRT4-overexpressing 
mice, suggesting increased mitochondrial oxidative stress as the 
cause. The authors proposed that SIRT4 may inhibit binding of 
SIRT3 to MnSOD, thereby increasing MnSOD acetylation and 
impairing H2O2 detoxification (88). Regarding IR injury in the 
heart, hypoxia downregulated the expression of SIRT4 in H9C2 
rat heart myoblasts, and knockdown of SIRT4 decreased cell 
viability, increased caspase activation, and increased the amount 
of apoptotic cells, suggesting that downregulation of SIRT4 dur-
ing hypoxia may contribute to increased apoptosis in response 
to hypoxia and IR (89). In contrast, SIRT4 siRNA treatment pro-
tected against induction of mPTP opening and mPTP-dependent 
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ROS production in another study, leaving the role of SIRT4 in 
myocardial IR injury incompletely elucidated (90).
SIRT5 also exerts only weak deacetylase activity, but instead 
catalyzes desuccinylation, demalonylation, and deglutaryla-
tion (91, 92). Large-scale proteomic analyses identified many 
proteins to be putative targets of SIRT5, including enzymes of 
amino acid degradation, the TCA cycle, FAO, pyruvate decar-
boxylation, and ATP synthesis (91). SIRT5 is highly expressed in 
cardiac tissue. Mice with deletion of SIRT5 develop cardiac dys-
function, pathologic hypertrophy, and increased fibrosis (93). 
Analysis of the cardiac succinylome in SIRT5−/− mice suggested 
mitochondrial energy metabolic pathways to be regulated by 
SIRT5, and that myocardial energy depletion may contribute 
to cardiac dysfunction in SIRT5−/− mice, potentially due in part 
to hypersuccinylation and inhibition of the FAO enzyme enoyl-
CoA hydratase α (93). Lack of SIRT5 also modulates the extent 
of IR injury. Myocardial infarct size was increased, and recovery 
of contractile function was impaired in hearts of SIRT5−/− mice 
following IR (94). IR injury was restored to WT levels by inhibi-
tion of succinate dehydrogenase, which was hypersuccinylated 
and probably more active in SIRT5−/− hearts. Since succinate 
accumulates during ischemia and drives mitochondrial ROS 
generation at the onset of reperfusion by increasing reverse 
electron transport in the respiratory chain, the authors pro-
posed that inhibition of succinate dehydrogenase may restore 
IR injury to WT levels by reducing succinate-driven ROS 
production (94, 95).
Taken together, both SIRT4 and SIRT5 may play a role in 
cardiac pathologies, and more studies are needed to further 
understand their mechanism of action. Deciphering the role 
of each mitochondrial sirtuin is important since some of the 
promising therapeutic approaches, in particular NAD+ reple-
tion, should increase the activity of all mitochondrial sirtuins 
simultaneously.
CONCLUSiON
Mitochondrial damage and dysfunction contribute to the 
pathogenesis of different cardiac pathologies, including heart 
failure and IR injury (30, 31, 62). Impairment in SIRT3 expres-
sion and/or activity has been proposed to contribute to these 
mitochondrial defects by slowing metabolic substrate oxidation, 
boostering mitochondrial oxidative stress, and increasing the 
sensitivity for mPTP induction. Based on beneficial effects on 
cardiac hypertrophy and IR injury by treatment with honokiol, 
resveratrol, and NMN, which increase the expression and/or 
activity of SIRT3, the development of specific SIRT3 activators 
could represent a novel therapeutic strategy by which multiple 
mitochondrial defects may be treated simultaneously. It needs 
to be kept in mind though that SIRT3 may interact with other 
mitochondrial sirtuins (SIRT4, SIRT5) as well; the myocardial 
functions of which are still poorly understood. Thus, more stud-
ies are needed to deepen our understanding of all mitochondrial 
sirtuins in cardiac physiology and disease. Based on our current 
knowledge, modulation of mitochondrial sirtuin activity seems 
to have great therapeutic potential and may advance the field of 
mitochondrial medicine also for diseases beyond cardiovascular 
disease.
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